35100-92-6

Basic information

• Product Name: 3-AMINO-1,5-DIMETHYLPYRAZOLE
• Synonyms: 3-AMINO-1,5-DIMETHYLPYRAZOLE;3-Amino-1,5-dimethyl-1H-pyrazole;(1,5-dimethylpyrazol-3-yl)amine;1,5-dimethyl-3-pyrazolamine;1,5-dimethylpyrazol-3-amine;1,5-Dimethyl-1H-Pyrazol-3-Ylamine(WX609107)
• CAS NO: 35100-92-6
• Molecular Formula: C₅H₉N₃
• Molecular Weight: 111.15
• Mol File: 35100-92-6.mol
• Article Data: 6

Chemical Properties

• Melting Point: 65-68 ºC
• Boiling Point: 235 ºC
• Flash Point: 96 ºC
• Appearance: /
• Density: 1.17
• Vapor Pressure: 0.0521mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: 2-8°C(protect from light)
• PKA: 4.17±0.11(Predicted)
• CAS DataBase Reference: 3-AMINO-1,5-DIMETHYLPYRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-1,5-DIMETHYLPYRAZOLE(35100-92-6)
• EPA Substance Registry System: 3-AMINO-1,5-DIMETHYLPYRAZOLE(35100-92-6)

Safety Data

• Statements: 20/21/22
• Safety Statements: 3/9-36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 35100-92-6(Hazardous Substances Data)

Usage

Chemical Properties

Yellow solid

InChI:InChI=1/C5H9N3/c1-4-3-5(6)7-8(4)2/h3H,1-2H3,(H2,6,7)

Upstream product

• 34362-22-6 2,3-dichlorobutanenitrile 
• 60-34-4 methylhydrazine 
• 25109-76-6 2,3-dibromobutanenitrile 
• 302-15-8 methylhydrazine sulfuric acid 
• 59376-16-8 1,5-dimethyl-3-nitro-1H-pyrazole 

Downstream Products

• 165333-66-4 N-(5⁽³⁾-methylpyrazol-3-⁽⁵⁾-yl)-2,6-dimethylbenzamide 
• 139297-17-9 N-(1,5-dimethylpyrazol-3-yl)-2,6-dimethylbenzamide 
• 887289-46-5 N-(1,5-dimethylpyrazol-3-yl)-2-fluoro-3-(trifluoromethyl)benzamide 
• 1354706-38-9 3-iodo-1,5-dimethyl-1H-pyrazole 
• 1271022-90-2 BMS-911543 
• 92133-82-9 N-(1,5-Dimethyl-1H-pyrazol-3-yl)-4-methyl-benzenesulfonamide 

Relevant articles and documents

A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND INTERMEDIATES THEREOF

The present invention relates to triaminopyrimidine compound 1, or pharmaceutically acceptable salts thereof, or hydrates, or solvates, or polymorphs, or optically active forms thereof, in solid state forms. The invention also relates to a process for preparation of triaminopyrimidine compound and intermediates thereof. The present invention also relates to a pharmaceutical composition comprising pure triaminopyrimidine compound, useful for preventing or treating malaria.

SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES

Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from -C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.